Refine by
Drug Treatment Articles & Analysis: Older
248 news found
Depression is a pervasive global health challenge that affects millions of individuals, with current treatment options often proving ineffective or inaccessible. With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop ...
(Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. ...
Alfa Chemistry provides a wide variety of these intermediates which meet strict quality and safety requirements required for the drug development process. These intermediates (ammonium acids, organic acids, esters and heterocyclic compounds) allow us to innovate in drug synthesis, which in turn leads to more effective and precise drugs. ...
Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its ...
Animal Hydrocolloids Animal-derived hydrocolloids are known for their strong protective colloid properties, good biocompatibility, stable batch, good mechanical strength, and that’s why they are extensively used as substrates or additives in many fields, including food, photography, cosmetics, artificial skin, wound dressings, ophthalmology, wastewater treatment, ...
Kelly Bugatti, BOC Sciences is set to host an informative webinar that will delve into the latest advancements in utilizing Peptide-Drug Conjugates (PDCs) for the targeted treatment of Pulmonary Fibrosi BOC Sciences has been organizing regular webinars in the fields of life sciences, drug discovery, and chemistry. ...
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. ...
This service is particularly valuable for developing treatments for drug-resistant bacterial infections, a growing concern in both healthcare and veterinary settings. ...
Traditional methods of evaluating the efficacy of oral medications have often been limited by the inability to accurately measure the drug's concentration in the body. This has led to challenges in determining the optimal dosage and timing of administration, which can impact both the effectiveness and safety of the treatment. ...
Adial announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD). ...
Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). ...
ByBayer AG
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid ...
Since China initiated antiretroviral treatment for AIDS, with the joint efforts of all prevention and treatment personnel, the ability to diagnose and treat AIDS has been greatly improved. In his speech, Hao Yang pointed out that in recent years, outstanding innovative drug companies such as Frontier Biotech have been deeply involved in the ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. ...
Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD). ...
Lenalidomide, as an oral immunomodulatory drug, revealed a good safety profile. Parecoxib Sodium Alfa Chemistry offers high-quality parecoxib sodium as API to support the amide prodrug of the cyclooxygenase II (COX-2)-selective inhibitor, non-steroidal anti-inflammatory drug (NSAID) valdecoxib, which has anti-inflammatory, analgesic, and antipyretic activities. ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug ...
(Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. ...
In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES). Non-responders had lower DS and survival than patients with high DS. ...
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. ...